{
    "clinical_study": {
        "@rank": "159760", 
        "arm_group": [
            {
                "arm_group_label": "BIOD-123", 
                "arm_group_type": "Experimental", 
                "description": "SC administration of 0.20 U/kg"
            }, 
            {
                "arm_group_label": "BIOD-125", 
                "arm_group_type": "Experimental", 
                "description": "SC administration of 0.20 U/kg"
            }, 
            {
                "arm_group_label": "Humalog", 
                "arm_group_type": "Active Comparator", 
                "description": "SC administration of 0.20 U/kg"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective is to assess the speed of absorption of BIOD-123 and BIOD-125 and\n      compare them to Humalog."
        }, 
        "brief_title": "Pharmacokinetic and Pharmacodynamic Properties of BIOD-123 and BIOD-125 Compared to Humalog\u00ae in Subjects With Type 1 Diabetes Including Assessments of Injection Site Toleration", 
        "completion_date": {
            "#text": "March 2012", 
            "@type": "Actual"
        }, 
        "condition": "Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1"
            ]
        }, 
        "detailed_description": {
            "textblock": "The primary objective is to assess the speed of absorption of BIOD-123 and BIOD-125 and\n      compare them to Humalog.\n\n      The secondary objectives are to assess other pharmacokinetic characteristics of BIOD-123 and\n      BIOD-125 and compare those to Humalog\u00ae, to assess pharmacodynamic characteristics of\n      BIOD-123 and BIOD-125 and compare those to Humalog\u00ae, and to evaluate the safety and\n      tolerability of BIOD-123 and BIOD-125 compared to Humalog\u00ae"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age: \u226518 - \u226470 years\n\n          2. BMI: \u226518 - \u226430 kg/m2\n\n          3. Diagnosed with type 1 diabetes mellitus for at least 1 year\n\n          4. Insulin antibody \u226410 \u03bcU/mL at screening\n\n        Exclusion Criteria:\n\n          1. Type 2 diabetes mellitus\n\n          2. History of >2 severe hypoglycemic events within the 3 months prior to screening\n\n          3. Serum C-peptide >1.0 ng/mL\n\n          4. Hemoglobin A1c (HbA1c) >10.0%\n\n          5. Females who were breast feeding, pregnant, or intending to become pregnant during the\n             study\n\n          6. A sexually active person who was not using adequate contraceptive methods\n\n          7. Positive serology for human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C\n\n          8. Abnormal ECG, safety lab, or physical examination results that were deemed clinically\n             significant by the investigator"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01908894", 
            "org_study_id": "3-101"
        }, 
        "intervention": [
            {
                "arm_group_label": "BIOD-123", 
                "intervention_name": "BIOD-123", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BIOD-125", 
                "intervention_name": "BIOD-125", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Humalog", 
                "intervention_name": "Humalog", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Insulin LISPRO"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "July 24, 2013", 
        "number_of_arms": "3", 
        "official_title": "A Double-blind Study of the Pharmacokinetic and Pharmacodynamic Properties of BIOD-123 and BIOD-125 Compared to Humalog\u00ae in Subjects With Type 1 Diabetes Including Assessments of Safety and Injection Site Toleration", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Subjects were to receive study drug at 3 separate dosing visits separated by 3-28 days. The estimated duration of study participation for 1 subject was approximately 12 weeks.  The estimated duration of the study was approximately 6 months.", 
            "measure": "Speed of absorption (TINS-50%-early) of BIOD-123 and BIOD-125 versus Humalog.", 
            "safety_issue": "No", 
            "time_frame": "0-30, 0-60, 0-90, 0-480, and 120-480 minutes"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01908894"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Biodel", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Biodel", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}